CNO (CNO) Q1 2026: Operating EPS Jumps 33% as Medicare Supplement and Worksite Sales Outperform

2026-05-01 | By EarningsIQ Research

CNO’s first quarter marked its fifteenth straight period of sales growth, powered by a sharp surge in Medicare Supplement and Worksite insurance sales, while operating discipline and product diversity kept margins stable despite pockets of claims volatility. Management’s capital return, agent expansion, and measured investment posture reinforce a durable, middle-market-focused model positioned for continued compounding. With robust agent productivity and strong asset growth, CNO’s execution signals further upside to long-term return targets, though macro and credit market uncertainty remain watchpoints.

Summary

• Medicare Supplement and Worksite Outperformance: Both divisions delivered double-digit new premium growth, highlighting resilient demand and effective distribution.
• Agent Productivity and Technology Leverage: Sustained agent growth and early AI-driven call center results are boosting sales momentum and customer experience.
• Capital Flexibility and Return Ambition: Management signals intent to raise return targets, underpinned by strong capital and liquidity, but remains cautious amid macro volatility.

Performance Analysis

CNO’s Q1 results underscore the strength of its diversified insurance model, with operating earnings per share up sharply and robust new annualized premium (NAP) growth across both Consumer and Worksite divisions. Consumer division sales rose for the fourteenth consecutive quarter, led by a 20% jump in total health NAP and a standout 24% increase in Medicare policies sold, as the industry-wide shift from Medicare Advantage to Medicare Supplement (MedSupp) played directly to CNO’s product mix and captive agent model. Life NAP grew modestly, though more than half of production now comes from direct-to-consumer (D2C) channels, which are increasingly digital.

The Worksite division continues to be a growth engine, with life and health NAP up 22% and agent count up for the fifteenth straight quarter. Supplemental health and long-term care blocks posted favorable margins, while annuity premiums saw a small decline on tough comps, offset by 7% growth in account values. Net investment income rose for the tenth consecutive quarter, driven by asset growth and new money rates above 6%.

• Medicare Supplement Acceleration: Policy sales surged as market disruption and regulatory changes drove switching, with CNO’s MedSupp up 53% in NAP despite modestly adverse claims experience.
• Worksite Momentum: Life insurance sales up 56% and hospital indemnity up 121%, fueled by new client wins and geographic expansion.
• Expense and Capital Management: Expense ratio came in below plan, with $60M deployed to share repurchases and robust liquidity supporting both growth and capital return.

Margin stability was maintained through product and investment diversification, even as MedSupp claims ticked up and annuity sales faced tough year-over-year comparisons. The company’s ability to drive agent productivity and asset growth, while flexibly managing expense and capital, remains a core differentiator.

Executive Commentary

Strategic Positioning

1. Middle Market Focus and Captive Agent Model

CNO’s business model is built around serving middle-income households through a proprietary, captive agent force—agents directly employed by the company, not independent brokers. This “last mile” distribution is positioned as a moat, enabling CNO to capitalize on demographic trends and regulatory shifts, especially as Medicare markets fragment and switching accelerates.

2. Product and Channel Diversification

Sales growth is broad-based, with Medicare Supplement, supplemental health, and Worksite products each posting strong gains. The D2C channel, especially for life insurance, is being modernized, with 65% of direct sales now sourced outside of traditional television, leveraging digital and third-party channels for lower cost and higher conversion.

3. Technology and AI-Driven Productivity

Investment in technology, data, and artificial intelligence (AI) is a growing strategic lever. Early pilots in the Colonial Penn call center are delivering shorter wait times and higher conversion rates, with further AI initiatives in the pipeline. These efforts aim to enhance both agent productivity and customer experience, providing operational leverage as scale increases.

4. Disciplined Capital Allocation and Return

CNO maintains a robust capital and liquidity position, with a risk-based capital ratio comfortably within target and holding company liquidity nearly double its minimum. The company continues to return capital through share repurchases and dividends, while signaling that return on equity (ROE) targets are poised to rise given sustained operating outperformance.

5. Investment Posture and Risk Management

The investment portfolio remains high quality and liquid, with new investments focused on shorter duration assets and a cautious approach to credit market volatility. Management is holding “dry powder” for more attractive opportunities, prioritizing capital efficiency and risk-adjusted returns over stretching for yield.

Key Considerations

This quarter’s results highlight the interplay of product demand, distribution leverage, and disciplined expense and capital management as CNO’s key value drivers. Investors should focus on:

• Medicare Market Disruption: Industry-wide plan terminations and slowing Medicare Advantage growth are fueling MedSupp switching, benefiting CNO’s mix and agent-led sales.
• Agent Force Expansion: Thirteen straight quarters of agent count growth and rising registered agents underpin consistent sales momentum and market penetration.
• Expense Ratio Leverage: Lower-than-expected Q1 expenses are likely to normalize, but business growth is driving favorable operating leverage.
• Capital Return Discipline: $77M returned to shareholders and a 7% reduction in share count demonstrate commitment to shareholder value, with further flexibility signaled by ample liquidity.
• Technology Adoption Pace: Early AI and digital channel gains are promising, but scale and sustained productivity improvements will be key to long-term margin expansion.

Risks

Volatility in claims experience, especially in Medicare Supplement and long-term care, could pressure margins if adverse trends persist beyond current rate actions. Credit market instability and macroeconomic headwinds may impact investment income or capital flexibility. Regulatory shifts in Medicare or broader health policy could disrupt product profitability or distribution. Finally, execution risk around technology investments and agent productivity remains, as scale and adoption are not guaranteed.

Forward Outlook

For Q2 2026, CNO guided to:

• Continued sales momentum in both Consumer and Worksite divisions, with agent productivity and retention expected to remain strong.
• Expense ratio normalization as planned spending resumes in coming quarters.

For full-year 2026, management affirmed guidance:

• Operating ROE target of 12% or above, with the likelihood of raising the 2027 target given current trajectory.

Management highlighted several factors that will shape the year:

• Medicare Supplement rate increases to address claims experience, with full benefit realized by Q4.
• Ongoing investment in technology and AI to drive efficiency and customer satisfaction.

Takeaways

CNO’s Q1 results reinforce the strength of its middle-market insurance platform, balancing growth, margin stability, and disciplined capital allocation. The company’s agent-led distribution and diversified product mix provide resilience and upside as market dynamics shift.

• Distribution and Product Mix Drive Growth: Double-digit premium increases in MedSupp and Worksite, underpinned by agent expansion and digital channel gains, position CNO for continued compounding.
• Capital and Margin Management Remain Robust: Strong liquidity and disciplined expense control support both reinvestment and shareholder return, with further upside to ROE targets signaled.
• Watch for Macro and Regulatory Shifts: Claims volatility, credit market moves, and Medicare policy changes are the key risks to monitor, alongside execution on technology and agent productivity initiatives.

Conclusion

CNO delivered another quarter of broad-based growth and margin stability, leveraging its captive agent model and diversified product suite to capitalize on market disruption and demographic tailwinds. With a measured approach to capital and technology investment, the company is well positioned to exceed its current return targets, though vigilance on claims, credit, and regulatory risks remains essential.

Industry Read-Through

CNO’s performance offers several signals for the broader insurance industry. The shift from Medicare Advantage to MedSupp amid regulatory and benefit disruption is creating switching opportunities for carriers with strong agent networks and product breadth. Agent productivity and retention are emerging as key differentiators, especially as digital and AI-driven tools enhance both customer experience and sales conversion. Capital discipline and selective investment posture are prudent in a volatile macro environment, with liquidity and flexibility providing a buffer against market shocks. Other insurers should note the importance of product and channel diversification to manage margin volatility and sustain growth through economic and regulatory cycles.

CNO Financials Insurance Medicare Agent Distribution Capital Return Technology Middle Market